The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key territories has introduced considerable uncertainty . Investors are now facing the consequences of